Kantify
Drug discovery
Kantify has developed ZeptoNet - a novel AI technology that can perform in silico high-throughput screening on small molecules. ZeptoNet can help accelerate the early drug discovery process, reduce clinical trials failure rate and help with drug repurposing.
Focus: Drug discovery platform
Team: Nik Subramanian and Segolene Martin
Website: https://www.kantify.com/
See other Drug discovery organisations
-
Enedra is harnessing the power of synthetic lethality and advanced computational Systems Biology to create therapeutics. -
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor (TCR)- based cancer immunotherapies. -
GlamorousAI is AI-first preclinical biotech focusing on the discovery of novel chemistry for challenging targets. -
Human Centric Drug Discovery helps patients with central nervous disorders by making it easier to develop drugs for their diseases.
Copyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.